Comparative Pharmacology
Head-to-head clinical analysis: MEZOFY versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZOFY versus TIGAN.
MEZOFY vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
12-15 hours; may be prolonged in hepatic impairment.
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antiemetic/Antivertigo
Antiemetic